News About: Pharm. Industry
Multinational pharmaceutical companies’ reasonable reorganization
Gigantic multinational pharmaceuticals have shown the instinct like a chameleon.
Although the instinct has always been found in history of the pharmaceutical industry, its method has never been same.
The keyword reg...
The 3-way competition of Pfizer, Lilly and Astellas in the oral RA treatment
As Pfizer, Lilly and Astellas entered the domestic oral rheumatoid arthritis treatment market, the 3-way competition has been formed.
Astellas Korea was recently approved for a clinical trial on its rheumatoid arthri...
About 10 mid-sized pharmaceutical companies are working on IPO
Domestic mid-sized pharmaceutical companies have attracted attention via IPO.
According to the industry concerned, at most 10 foreign and domestic companies, such as the largest Korean transfusion agent company affil...
The secret of a foreign company recording over KRW 70 billion only with 4 products is ‘specialization’
There is a foreign pharmaceutical company recording KRW 70 billion sales in the domestic market only with 4 product approvals.
The leading role of the drama is ‘Gilead Sciences Korea’ acquiring an approval for the ph...
Will the key leader of non-benefit products, filler, continuously grow? The answer will be shown at KRW 100 billion
Will the filler market, which has been in the limelight as a non-benefit medication, become a limitless gold mine for the pharmaceutical industry?
The filler market became a market worth of KRW 90 billion last year, ...
‘Ethical Management’ of pharmaceutical companies will get stricter as making performance records by self-diagnosis
A bill will be prepared to develop an indicator to assess the operational performance of ethical management by domestic pharmaceutical companies on their own and conduct inspe...
|
Cell therapy products collaborating with pharmaceutical companies increase in sales and expand to the global market
Domestic cell therapy products, collaborating with pharmaceutical companies, have recorded decent results.
Cell therapy products, successful to be commercialized through the venture boom in the ‘90s, were not able to...
The hepatitis B rivalry between BMS and Gilead will be continued in the hepatitis C market
The BMS-Gilead competitive composition, continued in the chronic hepatitis B treatment market, will revive even in the chronic hepatitis C treatment market.
Recently, BMS has made aggressive behaviors, such as the st...
The contraceptive ‘Mercilon’ triggered takeover competition of domestic pharmaceutical companies
Among domestic pharmaceutical companies, competition to take over the oral contraceptive ‘Mercilon’ is getting fiercer.
According to the industry, a part of the top domestic pharmaceutical companies are forming detai...
“The insurance benefit of Velcade as the primary treatment is urgently required”
An opinion was stressed again that the insurance benefit of ‘Velcade(generic name: bortezomib)’ needs to be extended for multiple myeloma patients to use as the primary treatment.
On the 22nd, Prefessor Jae-joong Lee...
